Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study

Koo, Taeryool; Lim, Do Hoon; Seol, Ho Jun; Park, Shin Young; Kim, Il Han; Chang, Jong Hee; Lee, Jeongshim; Jung, Shin; Gwak, Ho Shin; Cho, Kwan Ho; Hong, Chang Ki; Lee, Ik Jae; Kim, El; Kim, Jin Hee; Hong, Yong Kil; Jang, Hong Seok; Kim, Chae Yong; Kim, In Ah; Kim, Sung Hwan; Kim, Young Il; Kim, Eun Young; Kim, Woo Chul; Hong, Seok Jin

doi:10.1007/s11060-018-2839-z

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar concerns relating to treatment patterns for histologies apart from glioblastoma are apparent, although fewer data were available ( Table 3 ). Patients with low-grade gliomas frequently do not receive adequate therapy after surgery, with 30–40% of South Korean patients with grade 2 gliomas without any follow-up treatment after a non-gross total resection ( 145 ) and with 15% of US patients with anaplastic astrocytoma not receiving adjuvant therapy ( 149 ). As for glioblastoma, chemotherapy was frequently not sustained for ≥6 cycles, which were achieved, for example, by only 72% and 56% of elderly patients in France receiving TMZ and PCV, respectively, for high-grade IDH-mutant gliomas, while 19% and 87% in needed to reduce their chemotherapy dose ( 143 ).…”

Section: Treating Gliomamentioning

confidence: 99%

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

Pöhlmann,

Weller,

Marcellusi

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Gliomas are a group of heterogeneous tumors that account for substantial morbidity, mortality, and costs to patients and healthcare systems globally. Survival varies considerably by grade, histology, biomarkers, and genetic alterations such as IDH mutations and MGMT promoter methylation, and treatment, but is poor for some grades and histologies, with many patients with glioblastoma surviving less than a year from diagnosis. The present review provides an introduction to glioma, including its classification, epidemiology, economic and humanistic burden, as well as treatment options. Another focus is on treatment recommendations for IDH-mutant astrocytoma, IDH-mutant oligodendroglioma, and glioblastoma, which were synthesized from recent guidelines. While recommendations are nuanced and reflect the complexity of the disease, maximum safe resection is typically the first step in treatment, followed by radiotherapy and/or chemotherapy using temozolomide or procarbazine, lomustine, and vincristine. Immunotherapies and targeted therapies currently have only a limited role due to disappointing clinical trial results, including in recurrent glioblastoma, for which the nitrosourea lomustine remains the de facto standard of care. The lack of treatment options is compounded by frequently suboptimal clinical practice, in which patients do not receive adequate therapy after resection, including delayed, shortened, or discontinued radiotherapy and chemotherapy courses due to treatment side effects. These unmet needs will require significant efforts to address, including a continued search for novel treatment options, increased awareness of clinical guidelines, improved toxicity management for chemotherapy, and the generation of additional and more robust clinical and health economic evidence.

show abstract

Section: Treating Gliomamentioning

confidence: 99%

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

Pöhlmann,

Weller,

Marcellusi

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study

et al. 2018

View full text Add to dashboard Cite

show abstract

Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study

Abstract: A preference for RT and increased use of temozolomide was evident in the treatment pattern of LGG. The extent of resection was associated with a decision to perform RT and chemotherapy. To establish a robust guideline for LGG, further studies including molecular information are needed.

Cited by 2 publications

References 32 publications

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study

Contact Info

Product

Resources

About